[1] Mealy K，Feely J，Reid I，et al. Tumor marker detection in oesophageal carcinoma[J]. Eur J Surg Oncol，1996，22 (5)：505-507.

[2] Liu WL，Zhang G，Wang JY，et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma[J]. Biochem Biophys Res Commun，2008， 375 (3)：440-445.

[3] Chen JS，Chen KT，Fan WC，et al．Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer[J]. Clin Chem Lab Med，2010，48 (5)：719-725.

[4] Kijanka G，Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer[J]. J Proteomics， 2009，72 (6)：936-944.

[5] Baldwin RW. Tumour-associated antigens and tumour-host interactions [J]. Proc R Soc Med，1971，64 (10)：1039-1042.

[6] Anderson KS，LaBaer J. The sentinel within：exploiting the immune system for cancer biomarkers[J]. J Proteome Res，2005，4 (4)：1123-1133.

[7] Caron M，Choquet-Kastylevsky G，Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery[J]. Mol Cell Proteomics， 2007，6 (7)：1115-1122.

[8] Casey G，Lopez ME，Ramos JC，et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations inhuman malignancies[J]. Oncogene，1996，13 (9)：1971-1981.

[9] Engelhorn ME，Guevara-Pati?o JA，Noffz G，et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self [J]. Nat Med，2006，12 (2)：198-206.

[10] Spiotto MT，Reth MA，Schreiber H. Genetic changes occurring in established tumors rapidly stimulate new antibody responses[J]. Proc Natl Acad Sci USA，2003，100 (9)：5425-5430.

[11] Chen YT，Scanlan MJ，Sahin U，et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening [J]. Proc Natl Acad Sci USA，1997，94 (5)：1914-1918.

[12] Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis[J]. J Clin Invest， 2001，108 (10)： 1411-1415.

[13] Ward RL，Hawkins NJ，Coomber D，et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer[J]. Hum Immunol，1999，60 (6)：510-515.

[14] Mosolits S，Harmenberg U，Rudén U，et al. Autoantibodies against the tumor-associated antigen GA733-2 in patients with colorectal carcinoma [J]. Cancer Immunol Immunother，1999，47 (6)：315-320.

[15] Nesterova MV，Johnson N，Cheadle C，et al. Autoantibody cancer biomarker：extracellular protein kinase A[J]. Cancer Res，2006，66 (18)：8971-8974.

[16] Utz PJ，Anderson P. Posttranslational protein modifications，apoptosis， and the bypass of tolerance to auto antigens[J]. Arthritis Rheum， 1998， 41 (7)：1152-1160.

[17] Ullah MF，Aatif M. The footprints of cancer development：Cancer biomarkers[J]. Cancer Treat Rev， 2009，35 (3)：193-200.

[18] Blixt O，Bueti D，Burford B，et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis[J]. Breast Cancer Res， 2011，13 (2)：25.

[19] Liu L，Liu N，Liu B，et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer[J]. J Cancer Res Clin Oncol，2012，138 (10)：1737-1742.

[20] Sun Y，Zhang R，Wang M，et al. SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma[J]. Cancer Epidemiol Biomarkers Prev，2012，21 (11)：2043-2047.

[21] Olejek A，Damasiewicz-Bodzek A，Bodzek P，et al. Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma[J]. Int J Gynecol Cancer， 2009，19 (9)：1516- 1520.

[22] Liu WL，Guo XZ，Zhang LJ，et al. Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma[J]. BMC Cancer， 2010，10 (3)：467.

[23] Zhou JH，Zhang B，Kernstine KH，et al. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma[J]. World J Gastroenterol， 2011，17 (10)：1373-1378.

[24] Casiano CA，Mediavilla-Varela M，Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer[J]. Mol Cell Proteomics， 2006，5 (10)：1745-1759.

[25] O’Rourke DJ，Di-Johnson DA，Caiazzo RJ Jr，et al. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen[J]. Clin Chim Acta，2012，413 (5/6)：561-567.

[26] Chapman CJ，Thorpe AJ，Murray A，et al. Immunobiomarkers in small cell lung cancer：potential early cancer signals[J]. Clin Cancer Res， 2011，17 (6)：1474-1480.

[27] Kuboshima M，Shimada H，Liu TL，et al. Identification of a novel SEREX antigen，SLC2A1/GLUT1，in esophageal squamous cell carcinoma[J]. Int J Oncol，2006，28 (2)：463-468.

[28] Fujita Y，Nakanishi T，Hiramatsu M，et al．Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma[J]. Clin Cancer Res， 2006，12 (21)：6415-6320.

[29] Kilic A，Schuchert MJ，Luketich JD，et al. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum[J]. J Thorac Cardiovase Surg，2008，136 (1)：199-204．

[30] Wang X，Yu J，Sreekumar A，et al．Autoantibody signatures in prostate cancer[J]. N Engl J Med， 2005，353 (12)：1224-1235.

[31] Wu L，Chang W，Zhao J，et al．Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer[J]. Clin Cancer Res， 2010，16 (14)：3760-3768.